Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06753512 (VBIR) in Prostate Cancer
NCT02616185Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Dec 2015
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, Adenoviral Vectors, Plasmid DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06753512 and sasanlimab in prostate cancer (PCa), sponsored by Pfizer. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events, Number of Participants With AEs as Graded by NCI CTCAE v4.03 (Grade >= 3) and 2 more. Started Dec 2015; status: terminated.
02
Drugs
PF-06753512sasanlimab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02616185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616185.